Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Publications from the Centre for Immuno-Oncology

Targeting mitotic regulators in cancer as a strategy to enhance immune recognition.

Gregorczyk M. and Parkes EE., (2023), DNA repair, 132

Non-cell-autonomous cancer progression from chromosomal instability.

Li J. et al, (2023), Nature, 620, 1080 - 1088

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1.

Sugiyarto G. et al, (2023), Journal for immunotherapy of cancer, 11

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

Pencik J. et al, (2023), Molecular cancer, 22

cGAS-STING signalling in cancer: striking a balance with chromosomal instability.

Beernaert B. and Parkes EE., (2023), Biochemical Society transactions, 51, 539 - 555

Non-cell-autonomous cancer progression from chromosomal instability

Li J. et al, (2023), NATURE

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.

Fletcher CE. et al, (2022), Molecular cancer, 21

When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.

van Vugt MATM. and Parkes EE., (2022), Trends in cancer, 8, 174 - 189

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.

Parkes EE. et al, (2022), British journal of cancer, 126, 247 - 258

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments

Kopetz S. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40

A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA).

Lillie T. et al, (2022), CANCER RESEARCH, 82

A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY).

Lillie T. et al, (2022), CANCER RESEARCH, 82

Chromosomal instability shapes the tumor microenvironment through a chronic ER-stress response

Li J. et al, (2022), CANCER RESEARCH, 82

NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors

Lillie T. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40

The tumor microenvironment and immune responses in prostate cancer patients.

Kwon JTW. et al, (2021), Endocrine-related cancer, 28, T95 - T107

Development of Immunotherapy Combination Strategies in Cancer.

Yap TA. et al, (2021), Cancer discovery, 11, 1368 - 1397

The clinical and molecular significance associated with STING signaling in breast cancer.

Parkes EE. et al, (2021), NPJ breast cancer, 7

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.

Li J. et al, (2021), Cancer discovery, 11, 1212 - 1227

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.

Willenbrock F. et al, (2021), British journal of cancer, 124, 581 - 586

Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.

Harrington K. et al, (2021), CANCER RESEARCH, 81

Load More